医学
放射治疗
乳腺癌
乳房切除术
倾向得分匹配
队列
人口
阶段(地层学)
监测、流行病学和最终结果
内科学
流行病学
多元分析
比例危险模型
肿瘤科
逻辑回归
癌症
队列研究
外科
癌症登记处
古生物学
环境卫生
生物
作者
Peiwen Wu,Dongjie He,Shuchai Zhu,Hao Chang,Qiming Wang,Q. Shao,Gaiyan Li
出处
期刊:The Breast
[Elsevier]
日期:2022-06-22
卷期号:65: 41-48
被引量:6
标识
DOI:10.1016/j.breast.2022.06.004
摘要
This study aimed to investigate the role of postoperative radiation therapy in a large population-based cohort of patients with stage I-III male breast cancer (MaBC).Patients with stage I-III breast cancer treated with surgery were selected from the Surveillance, Epidemiology, and End Results cancer database from 2010 to 2015. Multivariate logistic regression identified the predictors of radiation therapy administration. Multivariate Cox regression model was used to evaluate the predictors of survival.We identified 1321 patients. Age, stage, positive regional nodes, surgical procedure, and HER2 status were strong predictors of radiation therapy administration. There was no difference between patients who received radiation therapy and those who did not (P = 0.46); however, after propensity score matching, it was associated with improved OS (P = 0.04). In the multivariate analysis of the unmatched cohort, the factors associated with better OS were administration of radiation therapy and chemotherapy. In the subset analysis of the unmatched cohort, postoperative radiation therapy was associated with improved OS in men undergoing breast-conserving surgery (BCS), with four or more node-positive or larger primary tumours (T3/T4). Furthermore, we found no benefit of radiation therapy, regardless of the type of axillary surgery in mastectomy (MS). In older MaBC patients with T1-2N1 who underwent MS, radiation therapy showed no significant effects, regardless of chemotherapy.Postoperative radiation therapy could improve the survival of MaBC patients undergoing BCS, with four or more node-positive or larger primary tumours. Moreover, it should be carefully considered in patients undergoing MS and older T1-2N1 patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI